Advertisement

Cancer Stem Cells (CSCs) and Their Application in Cancer Immunotherapy

  • Deepak Rohila
  • Yang YaoEmail author
  • Xuexiao Jin
Chapter
Part of the Stem Cells in Clinical Applications book series (SCCA)

Abstract

Cancer stem cells are a rare sub-population of cancer cells, responsible for metastasis, multiple differentiation, and tumor reoccurrence. These are one of the major reasons for the ineffectiveness of traditional cancer therapy, resulting in a relapse of many cancers. The current book chapter explores and characterizes immunological features of cancer stem cells and delves upon their significance for developing immunotherapy. We summarize: (1) characterization of cancer stem cells with comparison to general stem cells on the basis of molecular and specific CSC markers; (2) signaling pathways involved in therapy resistance of CSCs; (3) CSC niche and its contribution to tumor therapy; and (4) immunological response and comparison of current cancer stem cell-based immunotherapy. A detailed overview and better understanding of cancer stem cells and its correlation with immune system would provide a better insight for development of cancer stem cell-based immunotherapy.

Keywords

Cancer stem cell Immunology Cancer immunosurveillance 

Abbreviations

ALDH

Aldehyde dehydrogenases

AML

Acute myelocytic leukemia

CSC

Cancer stem cell

EMT

Epithelial-mesenchymal transition

LGR5

Leucine-rich repeat-containing G-protein coupled receptor 5

SMO

Smoothened

References

  1. Ahmed N, Abubaker K, Findlay J, Quinn M (2013) Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 114(1):21–34.  https://doi.org/10.1002/jcb.24317CrossRefPubMedGoogle Scholar
  2. Al-Dhfyan A, Alhoshani A, Korashy HM (2017) Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and beta-catenin and Akt activation. Mol Cancer 16:69.  https://doi.org/10.1186/s12943-017-0636-5CrossRefPubMedPubMedCentralGoogle Scholar
  3. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449(7165):1003–U1001.  https://doi.org/10.1038/nature06196CrossRefPubMedGoogle Scholar
  4. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M et al (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457(7229):608–U119.  https://doi.org/10.1038/nature07602
  5. Barr MP, Singh S, Foley E, He Y, Young V, Ryan R et al (2017) XRCC6BP1: a key player in cisplatin resistance and lung cancer stem cells. Lung Cancer 103:S1–S2CrossRefGoogle Scholar
  6. Bhatlekar S, Viswanathan V, Fields JZ, Boman BM (2017) Overexpression of HOXA4 and HOXA9 genes promotes self-renewal and contributes to colon cancer stem cell overpopulation. J Cell Physiol 233:727–735.  https://doi.org/10.1002/jcp.25981CrossRefPubMedGoogle Scholar
  7. Borovski T, Melo FDE, Vermeulen L, Medema JP (2011) Cancer stem cell niche: the place to be. Cancer Res 71(3):634–639.  https://doi.org/10.1158/0008-5472.Can-10-3220CrossRefPubMedGoogle Scholar
  8. Bruttel VS, Wischhusen J (2014) Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol 5:360.  https://doi.org/10.3389/fimmu.2014.00360CrossRefPubMedPubMedCentralGoogle Scholar
  9. Burnet M (1957) Cancer—a biological approach. 3. Viruses associated with neoplastic conditions. BMJ 1:841–846CrossRefGoogle Scholar
  10. Ceder J, Elgqvist J (2017) Targeting prostate cancer stem cells with alpha-particle therapy. Front Oncolgy 6:273.  https://doi.org/10.3389/fonc.2016.00273CrossRefGoogle Scholar
  11. Dighe AS, Richards E, Old LJ, Schreiber RD (1994) Enhanced in-vivo growth and resistance to rejection of tumor-cells expressing dominant-negative Ifn-gamma receptors. Immunity 1(6):447–456.  https://doi.org/10.1016/1074-7613(94)90087-6CrossRefPubMedGoogle Scholar
  12. Dionne LK, Driver ER, Wang XJ (2015) Head and neck cancer stem cells: from identification to tumor immune network. J Dent Res 94(11):1524–1531.  https://doi.org/10.1177/0022034515599766CrossRefPubMedPubMedCentralGoogle Scholar
  13. Duarte S, Momier D, Baqué P, Casanova V, Loubat A, Samson M, Guigonis JM, Staccini P, Saint-Paul MC, De Lima MP, Carle GF, Pierrefite-Carle V (2013) Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model. Stem Cells 31:423–432CrossRefGoogle Scholar
  14. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360.  https://doi.org/10.1146/annurev.immunol.22.012703.104803CrossRefPubMedGoogle Scholar
  15. Eaves CJ (2008) Cancer stem cells: here, there, everywhere? Nature 456(7222):581–582.  https://doi.org/10.1038/456581aCrossRefPubMedGoogle Scholar
  16. Ehrlich P (1909) Ueber den jetzigen Stand der Karzinomforschung. Vortrag gehalten vor den Studenten der Amsterdamer Universitaet, Vereinigung fuer wissenschaftliche Arbeit 1 June 1908. Printed in: P. Ehrlich[J]. Beitraege zur Experimentellen Pathologie und Chemotherapie, Akademische Verlagsgesellschaft, Leipzig. 118–164Google Scholar
  17. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY (2013) Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495(7440):241–245.  https://doi.org/10.1038/nature11979CrossRefPubMedPubMedCentralGoogle Scholar
  18. Frew AJ, Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P et al (2005) TRAIL-mediated immunosurveillance of malignancy. Tissue Antigens 66(5):420–420Google Scholar
  19. Hainaut P, Plymoth A (2013) Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 25(1):50–51.  https://doi.org/10.1097/CCO.0b013e32835b651eCrossRefPubMedGoogle Scholar
  20. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674.  https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMedPubMedCentralGoogle Scholar
  21. Holah NS, Aiad HAES, Asaad NY, Elkhouly EA, Lasheen AG (2017) Evaluation of the role of ALDH1 as cancer stem cell marker in colorectal carcinoma: an immunohistochemical study. J Clin Diagn Res 11(1):Ec17–Ec23.  https://doi.org/10.7860/Jcdr/2017/22671.9291CrossRefPubMedPubMedCentralGoogle Scholar
  22. Ivanov II, Honda K (2012) Intestinal commensal microbes as immune modulators. Cell Host Microbe 12(4):496–508.  https://doi.org/10.1016/j.chom.2012.09.009CrossRefPubMedPubMedCentralGoogle Scholar
  23. Ke J, Wu X, Wu X, He X, Lian L, Zou Y et al (2012) A subpopulation of CD24(+) cells in colon cancer cell lines possess stem cell characteristics. Neoplasma 59(3):282–288.  https://doi.org/10.4149/neo_2012_036CrossRefPubMedGoogle Scholar
  24. Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ (2017) Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater 16(4):489–496.  https://doi.org/10.1038/Nmat4822CrossRefPubMedGoogle Scholar
  25. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648.  https://doi.org/10.1038/367645a0CrossRefPubMedGoogle Scholar
  26. Luis Tume KP, Ubidia-Incio R, Moya J (2016) CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy. Gaceta Mexicana de Oncología 15(1):22–30CrossRefGoogle Scholar
  27. Lupia M, Cavallaro U (2017) Ovarian cancer stem cells: still an elusive entity? Mol Cancer 16:64.  https://doi.org/10.1186/s12943-017-0638-3CrossRefPubMedPubMedCentralGoogle Scholar
  28. Maccalli C, Volonte A, Cimminiello C, Parmiani G (2014) Immunology of cancer stem cells in solid tumours. A review. Eur J Cancer 50(3):649–655.  https://doi.org/10.1016/j.ejca.2013.11.014CrossRefPubMedGoogle Scholar
  29. Margaritescu C, Pirici D, Cherciu I, Barbalan A, Cartana T, Saftoiu A (2014) CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma. J Gastrointestin Liver Dis 23(2):161–170CrossRefGoogle Scholar
  30. Medema JP (2013) Cancer stem cells: the challenges ahead. Nat Cell Biol 15(4):338–344.  https://doi.org/10.1038/ncb2717CrossRefPubMedGoogle Scholar
  31. Melo FDE, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J et al (2017) A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature 543(7647):676–680.  https://doi.org/10.1038/nature21713CrossRefGoogle Scholar
  32. Miyata T, Oyama T, Yoshimatsu T, Higa H, Kawano D, Sekimura A et al (2017) The clinical significance of cancer stem cell markers ALDH1A1 and CD133 in lung adenocarcinoma. Anticancer Res 37(5):2541–2547.  https://doi.org/10.21873/anticanres.11597CrossRefPubMedGoogle Scholar
  33. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Ginestier C et al (2012a) Cancer stem cell vaccination confers significant anti-tumor immunity by selectively targeting cancer stem cells. J Clin Immunol 32(2):358–358Google Scholar
  34. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J et al (2012b) Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 72(7):1853–1864.  https://doi.org/10.1158/0008-5472.CAN-11-1400CrossRefPubMedPubMedCentralGoogle Scholar
  35. Picot T, Aanei CM, Fayard A, Flandrin-Gresta P, Tondeur S, Gouttenoire M et al (2017) Expression of embryonic stem cell markers in acute myeloid leukemia. Tumour Biol 39(7):1010428317716629.  https://doi.org/10.1177/1010428317716629CrossRefPubMedGoogle Scholar
  36. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434(7035):843–850.  https://doi.org/10.1038/nature03319CrossRefPubMedGoogle Scholar
  37. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107–1111.  https://doi.org/10.1038/35074122CrossRefPubMedGoogle Scholar
  38. Singh K, Jain M, Agarwal K, Pathania O (2017) Cancer stem cell marker, CD44 expression in Indian breast carcinoma patients and its association with the molecular subtypes of breast carcinoma. Breast 32:S105–S105CrossRefGoogle Scholar
  39. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2(4):293–299.  https://doi.org/10.1038/86297CrossRefPubMedGoogle Scholar
  40. Stigbrand T (2017) Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma (Retraction of Vol 35, Pg 11605, 2014). Tumor BiolGoogle Scholar
  41. Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic nude mice. Science 183(4124):534–536.  https://doi.org/10.1126/science.183.4124.534CrossRefPubMedGoogle Scholar
  42. Sullivan KE, Rojas K, Cerione RA, Nakano I, Wilson KF (2017) The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells. Oncotarget 8(14):22325–22343.  https://doi.org/10.18632/oncotarget.16479CrossRefPubMedPubMedCentralGoogle Scholar
  43. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171:280–287CrossRefGoogle Scholar
  44. Tachezy M, Zander H, Wolters-Eisfeld G, Muller J, Wicklein D, Gebauer F et al (2014) Activated leukocyte cell adhesion molecule (CD166): an “inert” cancer stem cell marker for non-small cell lung cancer? Stem Cells 32(6):1429–1436.  https://doi.org/10.1002/stem.1665CrossRefPubMedGoogle Scholar
  45. van den Broek MF, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK et al (1996) Decreased tumor surveillance in perforin-deficient mice. J Exp Med 184(5):1781–1790.  https://doi.org/10.1084/jem.184.5.1781CrossRefPubMedGoogle Scholar
  46. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29(29):235–271.  https://doi.org/10.1146/annurev-immunol-031210-101324CrossRefPubMedGoogle Scholar
  47. Wang J, Wu YY, Gao W, Li F, Bo YF, Zhu MX et al (2017a) Identification and characterization of CD133(+) CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer 8(3):497–506.  https://doi.org/10.7150/jca.17444CrossRefPubMedPubMedCentralGoogle Scholar
  48. Wang JH, Wang LW, Ho CT, Zhang KS, Liu Q, Zhao H (2017b) Garcinol from Garcinia indica downregulates cancer stem-like cell biomarker ALDH1A1 in nonsmall cell lung cancer A549 cells through DDIT3 activation. J Agric Food Chem 65(18):3675–3683.  https://doi.org/10.1021/acs.jafc.7b00346CrossRefPubMedGoogle Scholar
  49. Wang W, Li Y, Liu N, Gao Y, Li L (2017c) MiR-23b controls ALDH1A1 expression in cervical cancer stem cells. BMC Cancer 17:292.  https://doi.org/10.1186/s12885-017-3192-xCrossRefPubMedPubMedCentralGoogle Scholar
  50. Wang Y, Zhang C, Zhu H, Tang J, Zhang S, Luo J, Sun X (2017d) CD90 positive cells exhibit aggressive radioresistance in esophageal squamous cell carcinoma. J Thorac Dis 9(3):610–620.  https://doi.org/10.21037/jtd.2017.03.28CrossRefPubMedPubMedCentralGoogle Scholar
  51. Xiao M, Yan M, Zhang J, Xu Q, Qi S, Wang X, Chen W (2017) Cancer stem-like cell related protein CD166 degrades through E3 ubiquitin ligase CHIP in head and neck cancer. Exp Cell Res 353(1):46–53.  https://doi.org/10.1016/j.yexcr.2017.03.005CrossRefPubMedPubMedCentralGoogle Scholar
  52. Yanai H, Atsumi N, Tanaka T, Nakamura N, Komai Y, Omachi T et al (2017) Intestinal cancer stem cells marked by Bmi1 or Lgr5 expression contribute to tumor propagation via clonal expansion. Sci Rep 7:41838.  https://doi.org/10.1038/srep41838CrossRefPubMedPubMedCentralGoogle Scholar
  53. Yang R, An LY, Miao QF, Li FM, Han Y, Wang HX et al (2016) Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes. Oncotarget 7(24):35894–35916.  https://doi.org/10.18632/oncotarget.9116CrossRefPubMedPubMedCentralGoogle Scholar
  54. Zage PE, Whittle SB, Shohet JM (2017) CD114: a new member of the neural crest-derived cancer stem cell marker family. J Cell Biochem 118(2):221–231.  https://doi.org/10.1002/jcb.25656CrossRefPubMedGoogle Scholar
  55. Zhang WZ, Grivennikov SI (2013) Top Notch cancer stem cells by paracrine NF-kappa B signaling in breast cancer. Breast Cancer Res 15(5):316.  https://doi.org/10.1186/bcr3565CrossRefPubMedPubMedCentralGoogle Scholar
  56. Zhang L, Guo X, Zhang D, Fan Y, Qin L, Dong S, Zhang L (2017) Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Mol Carcinog 56:2022–2034.  https://doi.org/10.1002/mc.22656CrossRefPubMedGoogle Scholar
  57. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J et al (2009) Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458(7239):776–U117.  https://doi.org/10.1038/nature07737CrossRefPubMedPubMedCentralGoogle Scholar
  58. Zitvogel L, Kroemer G (2014) CD103(+) dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell 26(5):591–593.  https://doi.org/10.1016/j.ccell.2014.10.008CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Institute of ImmunologyZhejiang University School of MedicineHangzhouChina

Personalised recommendations